{"paper_id":"d7ca0f93-8e82-4752-affd-04f7a722fc71","body_text":"References\nKarten M.J., Rivier J. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists. Rationale and perspectives. Endocr. Rev. 7: 44, 1986.\nKnobil E. The neuroendocrine control of the menstrual cycle. Rec. Progr. Horm. Res. 36: 53, 1980.\nWildt L., Hausier A., Marshall G., Huchtinson J.S., Plant T.M., Belchetz P.E., Knobil E. Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology 109: 376, 1981.\nSandow J. Inhibition of pituitary and testicular function by GnRH analogues. In: Jeffcoate S.L., Sandler M. (Eds.), Progress towards a male contraceptive. John Wiley and Sons, Chichester, 1982, p. 19.\nConn P.M. The molecular basis of gonadotropin-releasing hormone action. Endocr. Rev. 7: 3, 1986.\nNaor Z., Childs G.V. Binding and activation of gonadotropin-releasing hormone receptors in pituitary and gonadal cells. Int. Rev. Cytol. 103: 147, 1986.\nClayton R.N., Catt K.J. Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocr. Rev. 2: 186, 1981.\nConn P.M., Hsueh A.J.W., Crowley W.F.Jr. Gonadotropin-releasing hormone: molecular and cell biology, physiology and clinical applications. Fed. Proc. 43: 2351, 1984.\nMillar R.P., Wormald P.J., Abrahamson M.J., Milton R.C., Mew R., Dutlow C.M., Blum M., Roberts J.L. GnRH and GnRH-precursor peptides in the regulation of luteinizing hormone and prolactin secretion from human pituitary cells. In: Motta M., Serio M. (Eds.), Hormonal therapy of prostatic disease: basic and clinical aspects. Medicom, London, 1988 in press.\nBhasin S., Swerdloff R.S. Mechanism of gonadotropin-releasing hormone action in the human male. Endocr. Rev. 7: 106, 1986.\nLahlan N., Roger M., Chaussain J.L., Feinstein M.C., Sultan C., Toublanc J.E., Schally A.V., Scholler R. Gonadotropin and α-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty. J. Clin. Endocrinol. Metab. 65: 946, 1987.\nMeldrum D.R., Tsao Z., Monroe S.E., Braunstein G.D., Sladek J., Lu J.K.H., Vale W., Rivier J., Judd H.L., Chang R.I. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J. Clin. Endocrinol. Metab. 58: 755, 1984.\nHsueh A.J., Jones P.B.C. Extrapituitary actions of gonadotropin-releasing hormone. Endocr. Rev. 2: 437, 1981.\nClayton R.N., Huhtaniemi I.T. Absence of gonadotropin-releasing hormone receptors in human gonadal tissue. Nature 299: 56, 1982.\nCorbin A., Bex F.J., Jones R. Comparison of LHRH agonist and antagonist: antifertility and therapeutic developments. In: F. Labrie, A. Belanger, A. Dupont (Eds.), LHRH and its analogues. Elsevier Science Publishers, Excerpta Medica, Amsterdam, 1984, p. 95.\nVickery B.H. Pharmacology of LHRH antagonists. In: B.J.A. Furr & A.E. Wakeling (Eds.), Pharmacology and clinical uses of inhibitors of hormone secretion and action. Bailliere Tindall, London, 1987, p. 387.\nHuchtinson F.G., Furr B.J.A. Sustained-release formulations of LHRH analogues. In: B.J.A. Furr & A.E. Wakeling (Eds.), Pharmacology and clinical uses of inhibitors of hormone secretion and action. Bailliere Tindall, London, p. 409, 1987.\nFraser H.M., Baird D.T. Clinical applications of LHRH analogues. Clin. Endocrinol. Metab. (Bailliere) 1: 43, 1987.\nBoepple P.A., Mansfield M.J., Wierman M.E., Rudiin C.R., Bode H.H., Crigler J.F.Jr., Crawford J.D., Crowley W.F.Jr. Use of a potent, long acting agonist of gonadotropin releasing hormone in the treatment of precocious puberty. Endocr. Rev. 7: 24, 1986.\nComite F., Jansen P. Bone density changes associated with GnRH analogues. Gynecol. Endocrinol. 2 (Suppl. 1): 105, 1988 (Abstract).\nWaibel S., Bremen Th., Schiff R., Scharia S., Wuster Chr., Ziegler R., Minne H.W., Leyendecker G. Bone density in patients treated with GnRH agonists for myomata and endometriosis. Gynecol. Endocrinol. 2 (Suppl. 1): 106, 1988 (Abstract).\nPeeling W. A phase III trial comparing ICI 118.630 (Zoladex) with orchiectomy in the management of advanced prostatic cancer. In: G.D. Chrisholm (Ed.), Zoladex — A nex treatment for prostatic cancer. Royal Society of Medicine Services International Congress and Symposium Series n. 125, 1987, p. 27.\nEdwards L., Phillips R.H., Allen L., Parmar H., Linghtman S. Orchidectomy vs. long-acting D-Trp6-LHRH in advanced prostatic cancer. Gynecol. Endocrinol. 2 (Suppl. 1): 56, 1988 (abstract).\nThe Leuprolide study group. Leuprolide versus diethylstibestrol for metastatic prostatic cancer. N. Engl. J. Med. 311: 1281, 1984.\nLabrie F., Dupont A., Belanger A., St. Arnaud R., Giguere M., Lacourciere Y., Emond J., Monfette G. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr. Rev. 7: 67, 1986.\nSchroeder F.H., Lock T.M.T.W., Chada D.R., Debruyne F.M.J., Karthaus H.F.M., De Jong F.H., Klijn J.G.M., Matroos A.W., De Voogt H. Metastatic cancer of the prostate managed with Buserelin, versus Buserelin. plus cyproterone acetate. J. Urol. 137: 912, 1987.\nEighth Congress of the European Association of Urology. London 18–21 may 1988, Abstracts 42-44.\nSerio M., Costantini A., Di Silverio F. Use of LHRH analogue “Zoladex” Depot alone and with cyproterone acetate in the treatment of advanced prostatic carcinoma. VIII International Symposium on Future Trends in Chemotherapy, 28–30 March 1988, Tirrenia (Pisa), p. 179 (Abstract).\nManni A., Santen R., Harvey H., Lypton A., Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr. Rev. 7: 89, 1986.\nWilliams M.R., Walker K.J., Turkes A. The use of an LHRH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br. J. Cancer 53: 629, 1986.\nKlijn J.G.M., van Geel A.N., Sandoz J., de Jong F.H. Endocrine pharmacokinetic and clinical effects of GnRH analogue treatment in patients with malignant and bennig breast disease. Gynecol. Endocrinol. 2 (Suppl. 1): 49, 1988.\nKlijn J.G.M. Long term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med. Oncol. Tumor Pharmacother. 1: 123, 1984.\nHarvey H.A., Lipton A., Max D.T. LHRH analogs for human mammary carcinoma. In: Vickery B.H., Nestor J.J., Hafez E.S.E. (Eds.), LHRH and its Analogues: Contraceptive and therapeutic applications. Lancaster MTP Press, 1986, p. 329.\nNicholson R.I., Walker K.J., Turkes A., Dyas J., Plowman P.N., Williams M., Blarney R.W. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J. Steroid Biochem. 235B: 843, 1985.\nMiller W.R., Scott W.N., Morris R., Fraser H.M., Sharpe R.M. Growth of human breast cancer cell line inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231, 1985.\nEidne K.A., Flanagan C.A., Millar R.P. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229: 989, 1985.\nComite F., Pescovitz O.M., Foster C.M., Cassorla F., Hench K., Mc Nemar A., Skerda M., Loriaux D.L., Cutler G.B.Jr. LHRH analog effect on pubertal development, growth and maturation in precocious puberty. In: F. Labrie, A. Belanger, A. Dupont (Eds.), LHRH and its analogues. Elsevier Science Publishers B.V., Excerpta Medica, Amsterdam p. 438, p. 438.\nRoger M., Chaussman J.L., Berlier P., Bost M., Canlorbe P., Colle M., François R., Garandeu P., Lahlan N., Morel Y., Schally A.V. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-Luteinizing Hormone Releasing Hormone microcapsules. J. Clin. Endocrinol. Metab. 62: 670, 1986.\nLaron Z., Kauli R., Schally A.V. Long term experience with a superactive GnRH analog (D-Trp-6-LHRH) in the treatment of precocious puberty. Review of 46 patients. Gynecol. Endocrinol. 2 (Suppl. 1): 39, 1988.\nWierman M.E., Beardsworth D.E., Mansfield M.J., Badger T.M., Crawford J.D., Cirgler J.F., Bode H.H., Laughlin J.S., Kushner D.C., Scully R.E., Hoffman W.H., Crowley W.F. Puberty without gonadotropins. A unique mechanism of sexual development. N. Engl. J. Med. 312: 65, 1985.\nHolland F.J., Fishman L., Bailey J.D., Fazekas A.T.A. Ketoconazole in the management of precocious puberty not responsive to LHRH analogue therapy. N. Engl. J. Med. 312: 1023, 1985.\nFoster C., Pescovitz O., Comite F., Shawker T., Loriaux D.L., Cutler G. Treatment of Mc-Cune Albright syndrome (MAS) with a luteinizing hormone-releasing hormone analog and with testolactone. Program of the VII International Congress of Endocrinology, Quebec City, Canada, 1984, p. 568 (Abstract).\nMeldrum D.R., Chang R.J., Lu J., Vale W., Rivier J., Judd H.L. Medical oophorectomy using a long-acting GnRH agonist — a possible new approach to the treatment of endometriosis. J. Clin. Endocrinol. Metab. 54: 1081, 1982.\nShaw R.W., Fraser H.M., Boyle H. Intranasal treatment with luteinizing hormone-releasing hormone agonist in women with endometriosis. Br. Med. J. 287: 1667, 1983.\nLemay A., Maheux R., Faure N., Jean C., Fazekas A.T.A. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil. Steril. 41: 863, 1984.\nSchriock E., Monroe S.E., Henzl M., Jaffe R.B. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil. Steril. 44: 583, 1985.\nHenzl M.R., Corson S.L., Moghissi K., Buttram V.C., Berqvist C., Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N. Engl. J. Med. 318: 485, 1988.\nCann C.E., Henzl M.R., Burry K. Reversible bone loss is produced by the GnRH agonist nafarelin. In: Cohn D.V., Martin T.J., Meunier P.J. (Eds.), Calcium regulation and bone metabolism: basic and clinical aspects. Elsevier, Amsterdam, 1987, p. 123.\nWilson E.A., Yang F., Rees E.D. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet. Gynecol. 55: 20, 1980.\nSoules M.R., Mc Carty K.S. Leiomyomatas: steroid receptor content. Am. J. Obstet. Gynecol. 143: 6, 1982.\nPerl V., Marquez J., Schally A.V., Comaru-Schally A.M., Leal G., Zacharias S., Gomez Lira C. Treatment of leiomyomata uteri with D-Trp-6-luteinizing-hormone releasing-hormone. Fertil. Steril. 48: 383, 1987.\nWest C.P., Lumsden MA, Lawson S., Williamson J., Baird D.T. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil. Steril. 48: 45, 1987.\nLumsden M.A., West C.P., Baird D.T. Goserelin therapy before surgery for uterine fibroids. Lancet i: 36, 1987.\nYen S.S.C. The polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 12: 177, 1980.\nAndreyko J.L., Monroe S.E., Jaffe R.B. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). J. Clin. Endocrinol. Metab. 63: 854, 1986.\nCouzinet B., Le Strat N., Brailly S., Schaison G. Comparative effects of cyproterone acetate or a long acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 63: 1031, 1986.\nSteingold K., De Ziegler D., Cedars M., Meldrum D.L., Lu J.K.H., Judd H.L., Chang R.J. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycistic ovarian disease. J. Clin. Endocrinol. Metab. 65: 773, 1987.\nCalogero A.E., Macchi M., Montanini V., Mongioi A., Maugeri G., Vicari E., Coniglione F., Sipione C., D’Agata R. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin releasing hormone. J. Clin. Endocrinol. Metab. 64: 980, 1987.\nFilicori M., Campaniello E., Michelacci L., Pareschi A., Ferrari P., Bolelli G., Flamigni C. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patient more susceptible to ovulation induction with pulsatile GnRH. J. Clin. Endocrinol. Metab. 66: 327, 1988.\nMuse K.N., Cetel N.S., Futterman L.A., Yen S.S.C. The premenstrual syndrome. Effects of “medical ovariectomy”. N. Engl. J. Med. 311: 1345, 1984.\nBancroft J., Boyle H., Fraser H.M. The use of an LHRH agonist in the treatment and investigation of the premenstrual syndrome. In: Kerns K.W., Harmanr A.J. (Eds.), Proceedings of the 13th Annual Meeting of International Foundation for Biochemical Endocrinology, Edinburgh. Plenum Press, New York, 1985, p. 456.\nFleming R., Coutts J.R. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertil. Steril. 45: 226, 1986.\nPorter R.N., Smith W., Craft I.L., Abdulwahid N.A., Jacobs H.S. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins. Lancet ii: 1285, 1984.\nSymposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, Switzerland, 18–21 February 1988. Abstracts n. 56-63 and 65-68. Gynecol. Endocrinol. 2 (Suppl. 1): 1988.\nNeveu S., Hedon B., Bringer J., Chinchole J.M., Arnal F., Humeau C., Gristol P., Viala J.L. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil. Steril. 47: 639, 1987.\nPalermo R., Amodeo G., Navot D., Rosenwarks Z., Cittadini E. Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles. Fertil. Steril. 49: 290, 1988.\nSerafini P., Stone B., Kerin J., Batzofin J., Quinn P., Marrs R. An alternate approach to controlled ovarian hyperstimulation in “poor responders”: pretreatment with a gonadotropin-releasing hormone analog. Fertil. Steril. 49: 90, 1988.\nPeters C.A., Walsh C.P. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N. Engl. J. Med. 317: 599, 1987.\nSalerno R., Moneti G., Forti G., Magini A., Natali A., Saltutti C., Di Cello V., Costantini A., Serio M. Simultaneous determination of testosterone, dihydrotestosterone and 5α-androstane, 3α, 17β, diol by isotopic dilution mass spectrometry in plasma and prostatic tissue of patients affected by benign prostatic hyperplasia. Effects of a 3-month treatment with a GnRH analog. J. Androl. 9: 234, 1988.\nGudmudsson J.A., Nillius S.J., Berqvist C. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six month’s clinical results. Fertil. Steril. 45: 817, 1986.\nLemay A., Faure N., Bastide A. Ovarian sonographic findings during intermittent luteinizing hormone releasing hormone agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach. Fertil. Steril. 47: 60, 1987.\nLemay A., Faure N., Labrie F., Fazekas A.T.A. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen induced bleeding. Fertil. Steril. 43: 868, 1985.\nKuhl H., Jung C., Taubert H.D. Contraception with an LHRH agonist: effect on gonadotropin and steroid secretion patterns. Clin. Endocrinol. (Oxf.) 21: 179, 1984.\nSchriock E.D., Monroe S.E., Martin M.C., Henzl M.R., Jaffe R.B. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin). Fertil. Steril. 43: 844, 1985.\nFraser H.M., Dewart P.J. Control of the menstrual cycle by LHRH and its analogues. Bibliography of reproduction 46: C1–C12, 1985.\nLinde R., Doelle G.C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by potent gonadotropin releasing hormone agonist in normal men. N. Engl. J. Med. 305: 663, 1981.\nBhasin S., Heber D., Steiner B.S., Handelsman D.J., Swerdloff R.S. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen. J. Clin. Endocrinol. Metab. 60: 998, 1985.\nPavlou S.N., Interland J.W., Wakefield G., Rivier J., Vale W., Rabin D. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone. J. Androl. 7: 228, 1986.\nGlode M.L., Robinson J., Gould S.F. Protection from cyclophosphamide induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet i: 1132, 1981.\nWaxman J.H., Ahmed R., Smith D. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother. Pharmacol. 19: 159,1987.\nAuthor information\nAuthors and Affiliations\nAdditional information\nPresented at the XXII National Meeting of the Italian Society of Endocrinology, Verona, June 15–18,1988.\nRights and permissions\nAbout this article\nCite this article\nForti, G. Clinicai applications of GnRH analogs. J Endocrinol Invest 11, 745–754 (1988). https://doi.org/10.1007/BF03350939\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/BF03350939","source_license":"public-domain-us","license_restricted":false}